At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 133 enrolled
Drug / intervention
GSK Biologicals' FluLaval® +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate Immune Responses Following A/California/7/2009 (H1N1)V-like Virus Vaccination Given 4 Months Following Seasonal Influenza Vaccination in Adults 19 to 40 Years of Age
In Brief
A Phase 1 clinical trial evaluating GSK Biologicals' FluLaval®, Placebo (saline), and 2 other interventions for Influenza. Completed, enrolled 133 participants across 3 sites.
Detailed Summary
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2010
Enrollment StartFeb 2010
Primary CompletionJan 2011
Study CompletionOct 2011
TodayJul 2026
First PostedFeb 1, 2010
Enrollment StartFeb 9, 2010
Primary CompletionJan 14, 2011
Study CompletionOct 21, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.4 years ago
Interventions
GSK Biologicals' FluLaval®biological
Intramuscular injection
Placebo (saline)biological
Intramuscular injection
GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274Abiological
Intramuscular injections
GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273Abiological
Intramuscular injections